tiprankstipranks
Advertisement
Advertisement

ARWR Stock Latest News

Entera Bio Is Building the Future of Peptides Beyond the Needle (NASDAQ: ENTX)
TipRanks NewswireEntera Bio Is Building the Future of Peptides Beyond the Needle (NASDAQ: ENTX)
3d ago
NVO
ARWR
Arrowhead’s Inhaled ARO-RAGE Asthma Trial Enters Active Recruitment, Keeping a Key Pipeline Catalyst in Play
PremiumCompany Announcements
Arrowhead’s Inhaled ARO-RAGE Asthma Trial Enters Active Recruitment, Keeping a Key Pipeline Catalyst in Play
7d ago
ARWR
Arrowhead Pharmaceuticals: Buy Rating Reaffirmed as ARO-INHBE Data Strengthen Outlook and $100 Price Target Maintained
PremiumRatings
Arrowhead Pharmaceuticals: Buy Rating Reaffirmed as ARO-INHBE Data Strengthen Outlook and $100 Price Target Maintained
7d ago
ARWR
Arrowhead presents interim results from Phase 1/2a trial of ARO-INHBE
PremiumThe Fly
Arrowhead presents interim results from Phase 1/2a trial of ARO-INHBE
8d ago
ARWR
Arrowhead presents clinical cardiometabolic data at EAS Congress
PremiumThe Fly
Arrowhead presents clinical cardiometabolic data at EAS Congress
9d ago
ARWR
Arrowhead’s ARO-C3 Kidney Trial Reaches Completion, Setting Up the Next Catalyst for ARWR Investors
PremiumCompany AnnouncementsArrowhead’s ARO-C3 Kidney Trial Reaches Completion, Setting Up the Next Catalyst for ARWR Investors
13d ago
ARWR
Arrowhead’s ARO-CFB Kidney Trial Completion: What Investors Should Watch Next
Premium
Company Announcements
Arrowhead’s ARO-CFB Kidney Trial Completion: What Investors Should Watch Next
15d ago
ARWR
Arrowhead price target raised to $46 from $35 at Bernstein
Premium
The Fly
Arrowhead price target raised to $46 from $35 at Bernstein
22d ago
ARWR
Arrowhead Pharmaceuticals’ Earnings Call: Launch, Losses, Bets
PremiumCompany Announcements
Arrowhead Pharmaceuticals’ Earnings Call: Launch, Losses, Bets
26d ago
ARWR
Arrowhead price target raised to $90 from $80 at Chardan
PremiumThe Fly
Arrowhead price target raised to $90 from $80 at Chardan
27d ago
ARWR
Arrowhead reports Q2 EPS (93c), consensus ($1.11)
PremiumThe Fly
Arrowhead reports Q2 EPS (93c), consensus ($1.11)
27d ago
ARWR
Arrowhead announces exclusive worldwide license agreement with Madrigal Pharma
PremiumThe Fly
Arrowhead announces exclusive worldwide license agreement with Madrigal Pharma
30d ago
ARWR
MDGL
Is ARWR a Buy, Before Earnings?
PremiumPre-EarningsIs ARWR a Buy, Before Earnings?
30d ago
ARWR
Arrowhead announces Australian TGA approved Redemplo for FCS
Premium
The Fly
Arrowhead announces Australian TGA approved Redemplo for FCS
1M ago
ARWR
Arrowhead initiated with an Overweight at JPMorgan
Premium
The Fly
Arrowhead initiated with an Overweight at JPMorgan
1M ago
ARWR
Arrowhead, Astera, Exxon, Intel, Halliburton Trending With Analysts
PremiumWeekend Updates
Arrowhead, Astera, Exxon, Intel, Halliburton Trending With Analysts
1M ago
HAL
XOM
Arrowhead announces EMA recommended approval of Redemplo
PremiumThe Fly
Arrowhead announces EMA recommended approval of Redemplo
1M ago
ARWR
Intel upgraded, Reddit initiated: Wall Street’s top analyst calls
PremiumThe Fly
Intel upgraded, Reddit initiated: Wall Street’s top analyst calls
1M ago
CL
MHK
Arrowhead upgraded to Overweight from Equal Weight at Morgan Stanley
PremiumThe Fly
Arrowhead upgraded to Overweight from Equal Weight at Morgan Stanley
1M ago
ARWR
Arrowhead price target raised to $93 from $81 at BofA
PremiumThe FlyArrowhead price target raised to $93 from $81 at BofA
1M ago
ARWR
Arrowhead presents long-term efficacy, safety data for plozasiran
Premium
The Fly
Arrowhead presents long-term efficacy, safety data for plozasiran
2M ago
ARWR
Maintaining Buy on Arrowhead: APOC3-Driven Value Unlocked by Shasta-3/4 Amid Obesity Program Uncertainty
Premium
Ratings
Maintaining Buy on Arrowhead: APOC3-Driven Value Unlocked by Shasta-3/4 Amid Obesity Program Uncertainty
2M ago
ARWR

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >